cyrilzakka/clinical-trials huggingface dataset:
Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C

This project is a prospective observational cohort study to quantify the risk of acquiring Hepatitis C virus (HCV) infection for patients and healthcare workers in Ain Shams University Teaching Hospital, Cairo, Egypt through: 1) identifying typical patient trajectories within the hospital; and 2) assessing the ward-specific risk based on the type and number of procedures performed and the prevalence of HCV viremia in patients within each ward.

Hepatitis C virus (HCV) is a blood-borne virus and its major route of transmission include blood transfusion, medical injection and procedure, and injecting drug use. In Egypt, the origin of the HCV epidemic has been attributed to a mass treatment of schistosomiasis between 1960 and 1984, when intravenous injections with antimony salts were given to 3-5 million people older than 6 years of age. Insufficient sterilization of needles and syringes was considered to be responsible for HCV transmission at that time. In order to control the spread of HCV in Egypt, the Egyptian Ministry of Health and Population established the National Committee for the Control of Viral Hepatitis. By 2008, this committee developed a National Control Strategy for Viral Hepatitis which has recommended prevention and education campaigns targeting general population and also healthcare workers (HCW). In their occupational environment, HCWs are frequently exposed to multiple blood-borne pathogens, including HCV. Several risk factors for HCV acquisition among patients and HCWs within a hospital ward have been identified, including a high prevalence of HCV infection in the ward, understaffing, workplace characteristic, and human factors such as inexperience or unfamiliar with equipment. However, to the investigators' knowledge, the overall risk of HCV acquisition associated with hospital stay has never been evaluated in Egypt. Also, control measures to reduce the risk of HCV transmission in hospital settings, based on a global assessment of healthcare provider logistics and performance, have never been proposed in Egypt.

In this project, the investigators assume that HCV will be transmitted to both hospital staff and patients. Given the slow dynamics of the HCV epidemic, the investigators further hypothesize that, in the short term, the prevalence of HCV viremia among patients will be constant. Therefore, the investigators are led to conclude that HCV transmission risk may be inferred from a detailed description of individual trajectories of patients or staff within the hospital.

Eligibility Criteria:
Inclusion Criteria for patients:

* Aged 21 years or older
* Staying in the hospital more than 24 hours
* Provided a written informed consent to participate

Inclusion Criteria for healthcare workers:

* Aged 21 or older
* Provided a written informed consent to participate
The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia

This randomized, double-blinded, placebo-controlled, crossover clinical trial aims to investigate the effect of VGH-BPH1, a scientific Chinese medicine powder prescription, on patients with benign prostatic hyperplasia.

Benign prostatic hyperplasia (BPH) is an enlargement of the prostate gland due to progressive hyperplasia of the stromal and glandular cells.

The aim of this study is to evaluate the efficacy of traditional Chinese medicine (VGH-BPH1) in treating patients with BPH, by using the experimental BPH-1 powder, including Ji Sheng Shen Qi Wan and Sangpiaoxiao powder as the main prescription, and adding Wuyao, Yizhiren, Danshen, Yinyanghuo, Fupenzi, Huangbo and Zhimu as auxiliary ingredients, to form a 5gm per pack. This study is designed as a double-blinded randomized placebo-controlled cross-over trial to provide experimental evidence and feasibility of traditional Chinese medicine VGH-BPH1 in the treatment of BPH, and to analyze the syndrome pattern of Chinese medicinal prescriptions for subgroups of BPH.

Eligibility Criteria:
Inclusion Criteria:

* Patients who have been diagnosed with benign prostatic hyperplasia by a urologist
* Have been treated with conventional first-line western medicine for more than three months
* Patients with moderate to severe benign prostatic hyperplasia (IPSS score \>12 points)
* Participate voluntarily in the study

Exclusion Criteria:

* At the same time, use other Chinese herbal medicines or alternative medicine (including drugs and acupuncture) for more than one month.
* Syphilis, gonorrhea and other sexually transmitted diseases or urinary tract infections
* Urinary tract stones, prostate cancer, bladder cancer or acute and chronic renal failure
* Congenital abnormalities such as bladder neck fibrosis, interstitial cystitis or urethral stricture
* A history of genital trauma or surgery affecting the muscle or nervous system
* Patients with upper urinary tract obstruction, renal edema, etc. affecting renal function
* Unable to sign a consent form or unable to communicate with researchers
Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?

The purpose of this study is to compare exposure to general anesthesia between cases with a diagnosis of Alzheimer´s disease and controls without diagnosis, through studies of medical records. The investigators wish to explore if there is a relationship between exposure to general anesthesia and the development of Alzheimer´s disease.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of Alzheimer´s disease
* Previous exposure to anesthesia

Exclusion Criteria:

* Inability to retrieve medical records
Gentle Yoga and Dietary Counseling in Improving Physical Function and Quality of Life in Stage I-II Endometrial Cancer Survivors

This randomized clinical trial studies how well gentle yoga and dietary counseling lifestyle change effects physical function and quality of life of endometrial cancer survivors. Gentle yoga and dietary counseling may help improve physical function and quality of life for stage I-II endometrial cancer survivors.

PRIMARY OBJECTIVES:

I. To determine the feasibility and efficacy of a combined lifestyle intervention (yoga + diet) to positively impact physical function and quality of life for endometrial cancer survivors.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.

ARM II: Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.

Eligibility Criteria:
Inclusion Criteria:

* English speaking
* Previous diagnosis of grade 1 or 2, stage I or II endometrioid endometrial cancers ("type I cancers") as confirmed during surgical intervention for treatment
* Overweight or obese (\> 25 kg/m\^2)
* Anytime from treatment
* Treating oncologist consent
* Primary physician consent to engage in physical activity unsupervised
* Ambulatory or able to engage in walking for at least 15 minutes
* Sedentary lifestyle, as engaging in less than 100 minutes structured aerobic walking, cycling or swimming per week

Exclusion Criteria:

* No prior type I endometrial cancer diagnosis
* Prior diagnosis of other cancer
* Currently (previous 6 months) engaged in structured exercise either aerobic or yoga based
* Severe heart or systemic disease: evidence of documented myocardial infarction, chronic unstable angina, symptomatic congestive heart failure, uncontrolled hypertension
* Severe musculoskeletal disease: severe muscle or joint disorders due to disease or trauma, amputations, or any condition that significantly impair physical capabilities, as defined by the physician
* Non-ambulatory
* Concurrent diagnosis of organic brain syndrome, dementia, mental retardation, or significant sensory deficit
* Major mental illness (e.g., schizophrenia, major depressive disorder)
* Unwilling to give consent
Medical Cooling of Ice Hockey Players

The incidence of Sports-related concussions (SRCs) has risen in recent years, not least in ice hockey, and available treatment options are limited. Here, we addressed the hypotheses that immediate controlled head- and neck cooling could hasten return-to-play in a Swedish cohort of concussed professional ice hockey players. Over three seasons, 15 teams used either immediate head- and neck cooling or standard management for SRC. All players (81) followed the same return-to-play management protocol.

Sports-related concussions (SRCs) are a growing health concern, since they may lead to persistent symptoms and, particularly if repeated, to e.g. depression, accelerated dementia onset, and development of chronic traumatic encephalopathy. Here, we addressed the hypotheses that immediate controlled head- and neck cooling could hasten return-to-play in a Swedish cohort of concussed professional ice hockey players. Over three seasons, 15 teams used either immediate head- and neck cooling or standard management for SRC. All players followed the same return-to-play management protocol. Using a baseline questionnaire, no difference in the number of previous SRCs between groups was observed. In total, 92 SRCs were recorded. Eleven players did not complete the study protocol, and thus 81 players were included. Of these, 29 were treated by immediate selective head- and neck cooling for ≥ 30 min, and 52 controls received standard acute SRC management.

Eligibility Criteria:
Inclusion Criteria:

* Elite ice hockey players diagnosed by a team physician to have suffered a sports-related concussion. Selective head-neck cooling following the concussion. Duration of cooling a minimum of 45 minutes.

Exclusion Criteria:

* Presence of red flags (loss of consciousness, seizure, worsening headache, repeated vomiting, focal neurological deficits, neck pain, tingling in arms). Inability to tolerate cooling for a minimum of 30 minutes. Age \<18 years old.
Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan

Streptococcus pneumoniae is a major cause of pneumonia, among infants and children in Japan and worldwideThis study plans to investigate the rate of invasive pneumococcal disease "IPD " and the rate of hospitalizations due to pneumonia in Okinawa and the Eastern half of Hokkaido Currently, only a limited information about pneumococcal disease burden is available in Japan.


Eligibility Criteria:
Eligibility Criteria

- Children residing in the surveillance area(s) aged 28 days to \<60 months with clinical suspicion of pneumonia, meningitis and bacteremia who were admitted to the hospital.
Charlson Comorbidity Index and Outcome of Cardiopulmonary Resuscitation in Geriatric Patients in Hong Kong

The goal of this observational study is to learn about the factors affecting the outcome (survival) of cardiopulmonary resuscitation in older persons in a hospital. The main questions it aims to answer are:

* Whether age would affect outcome
* Whether Charlson Comorbidity Index would affect outcome
* Whether the conditions (e.g. heart rhythm) immediately before resuscitation would affect survival.

Researchers would compare the patients who deceased with the patients who survived.

The goal of this review was to investigate the impact of age, existing medical conditions. and other factors before cardiac arrest in predicting outcome of in-hospital cardiopulmonary resuscitation (CPR) of older persons.

It was conducted on all patients aged ≥ 65, who underwent CPR in acute medical and geriatric wards (excluding Intensive Care Unit) in United Christian Hospital from January 2017 to December 2018.

Eligibility Criteria:
Inclusion Criteria:

* All adults aged 65 or above with in-hospital cardiac arrest and undergoing CPR in wards of Department of Medicine and Geriatrics (excluding Intensive Care Unit (ICU)) in United Christian Hospital (total bed 1,174 with 16 ICU beds) in Hong Kong from 1 January 2017 to 31 December 2018
* In patients with multiple resuscitation events, only the first in-hospital CPR was included.

Exclusion Criteria:

* Patients with existing Do-Not-Attempt-Cardiopulmonary-Resuscitation (DNACPR) order
* Patients younger than 65 years old
* Out-of-hospital CPR in the index admission
* CPR occurred in ICU / Emergency Department / Operating Theatre / wards other than medical wards
Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer

The trial population of this study is composed of women aged more than 18, who have developed a newly node-negative (or pN1mi), Estrogen Receptor (ER)-positive, Her2-negative invasive breast cancer with uncertainty on the indication of adjuvant chemotherapy using standard assessments.

Obtaining material for test is at no risk as done from the surgery material. Tumor molecular EndoPredict (EP)clin analysis will allow to obtain information on the expression of 8 breast cancer related genes and will provide important prognosis indications. Clinical validation studies have demonstrated that molecular assays are useful for stratifying patients into risk categories and helpful in making clinical treatment decisions in ER+/node-negative breast cancer patients.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years,
* Performance status 0 or 1,
* Patient with newly diagnosed, previously untreated, unilateral, localized, histologically confirmed, invasive breast cancer
* Fully operated breast cancer including complete resection of breast tumor and adequate axillary surgery
* Available surgical material (formalin-fixed, paraffin-embedded) for EPclin® evaluation
* ER-positive by IHC (\>10% cells stained or Allred Score≥4)
* HER2-negative by IHC (score 0 or 1+) and/or Fish/Cish
* Node-negative or pN1mi (through axillary lymph node examination using sentinel node biopsy or axillary clearance)
* Uncertainty regarding the toxicity/benefit of adjuvant chemotherapy, outlined inthe following situations:

  * Lobular histology
  * Or grade II
  * Or grade III and pT \< 2cm
* Adequate renal, hepatic, cardiac and hematopoietic functions for a chemotherapy administration
* Willingness and ability to comply with scheduled visits as well as with test results and chemotherapy decision according to the latest
* Signed informed consent and Health insurance coverage

Exclusion Criteria:

* Non operable, bilateral, locally advanced, T4 or metastatic breast cancer
* Any lymph node involvement with the exception of pN0i+ or pN1mi
* HER2 Overexpression
* Diagnosis of any previous malignancy within the last 5 years, except for adequately treated basal cell carcinoma, or squamous cell skin carcinoma, or in situ cervical carcinoma
* Any previous systemic or locoregional treatment for the present breast cancer
* Documented inherited predisposition with BRCA1/2 or TP53 mutation
* Previous hormone replacement therapy (HRT) stopped less than 2 weeks before surgery
* Previous treatment for the present breast cancer
* Person unable to give informed consent
Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule

Efficacy and safety of two new formulations compared to Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections was evaluated in this randomized, three-arms, multicentral study.

This was a national, randomized, 3-arms, phase III study conducted in 16 centers in Türkiye.

It was aimed to evaluate the efficacy and safety of different fixed dose vaginal ovule formulations of fenticonazole + tinidazole + lidocaine (Formulation A and Formulation B) in the treatment of bacterial vaginosis, candidal vulvovaginitis, trichomonal vaginitis and mixed infections with comparison to Gynomax® XL vaginal ovule.

Eligibility Criteria:
Inclusion Criteria:

1. Female patients with age of ≥ 18 and ≤ 55 years who have a regular menstrual cycle (at least 10 times a year)
2. Female patients who previously experienced vaginal intercourse
3. Patients requiring treatment for bacterial vaginosis, candidal vulvovaginitis, trichomonal vaginitis or mixed infections according to the investigator's decision
4. Signed informed consent

Exclusion Criteria:

1. Known hypersensitivity to active ingredients (including their derivatives) of the study medications
2. Vaginismus, endometriosis, dyspareunia
3. Detection of urinary tract infection in urinalysis
4. Pancreatitis, hypertriglyceridemia, liver diseases, benign or malign tumors and ongoing organ failure
5. Usage of herbal medicines and drugs that interfere with microsomal enzymes, especially cytochrome P450 (phenytoin, phenobarbital, primidone, carbamazepine, rifampicin, topiramate, felbamate, griseofulvin, HIV protease inhibitors such as ritonavir, nucleoside reverse transcriptase inhibitors such as efavirenz)
6. History of cardiovascular event
7. Uncontrolled diabetes and hypertension
8. Presence or known risk or of venous or arterial thromboembolism
9. Undiagnosed abnormal vaginal bleeding, bleeding disorders, bleeding due to intrauterine device implantation during study period, presence of genital tumors
10. Use of drugs containing ombitasvir / paritaprevir / ritonavir or dasabuvir during or two weeks before initiation of the study
11. Pregnancy and/or breastfeeding
12. Participation in any other trial 30 days before initiation of the study
13. Postmenopausal women
14. Chronic alcoholism
15. Patients with organic neurological disorders
16. Patients with blood dyscrasia or with a history of blood dyscrasia
17. Usage of medications containing acenocoumarol, anisindione, dicoumarol, phenindione, phenprocoumon, warfarin, cholestyramine, cimetidine, cyclosporine, disulfiram, fluorouracil, fosphenitoin, ketoconazole, lithium, rifampin, tacrolimus or propranolol
18. Presence of a sexually transmitted disease such as syphilis, gonorrhea, chlamydia etc. according to the investigator's decision
19. Patients who cannot perform sexual abstinence during the study
20. Patients whose treatment may be affected due to sagging of uterus or any other anatomical disorder
Physical Activity, Insulin Resistance and Function of Fat Tissue in the Offspring of Patients With Type 2 Diabetes

Offspring of patients with type 2 diabetes have increased risk of developing diabetes and are typically more insulin resistant than their peers with no diabetes family history. We have recently demonstrated that, in contrast to their sedentary counterparts, physically active offspring are not insulin resistant. In the proposed controlled clinical study, we will examine the effects of a moderate exercise programme on insulin resistance, and other metabolic risk factors, in sedentary offspring and matched control subjects. We hypothesise that offspring will exhibit an augmented response to exercise, thereby normalising their predisposition to an adverse metabolic profile. We will also investigate expression of adipokines and other genes in adipose tissue to determine whether these contribute to the increased insulin resistance observed in offspring and whether they are influenced by exercise. The results will help to determine the efficacy of exercise in normalising metabolism in offspring and will help elucidate the mechanisms involved.


Eligibility Criteria:
Inclusion Criteria:

* 2 subject groups - 'control' and 'offspring'
* Offspring - at least 1 parent diagnosed with type 2 diabetes before age 65
* Controls - no history of type 2 diabetes in 1st or 2nd degree relatives
* In generally good health
* Non-smoker
* Fasting glucose \< 7 mmol/l
* Blood pressure \<160/90 mm Hg
* No established CHD (e.g. MI, stroke, CABG, PCTA)

Exclusion Criteria:

* Established CHD (e.g. MI, stroke, CABG, PCTA)
* diabetes
* smoking
* hypertension (BP \> 160/90 mmHg)
* pregnancy
Effect of Concentrated Growth Factors on Healing of Apicomarginal Defects: a Prospective Study

The persistent and chronic apical periodontitis has caused great difficulties for clinical physicians. Ensuring rapid and successful healing of the extensively damaged periapical region is a pressing issue that needs to be addressed. The treatment options include traditional apical surgery, simultaneous placement of bone powder and membrane after apical surgery, and simultaneous placement of sticky bone (bone powder mixed with concentrated growth factors gel) and membrane. However, high-quality evidence regarding these various treatment options is scarce. The purpose of this study is to compare the advantages and disadvantages of each treatment option, in order to guide clinical physicians in the application of apical surgery.

This prospective study will recruit 72 patients with chronic periapical periodontitis in their anterior teeth or premolars, all of which have received comprehensive root canal treatment. The patients will be randomly divided into four groups: Group A, which will undergo only apical surgery (including apicoectomy, inflammation debridement, and retrofilling of the root apex); Group B, which will undergo apical surgery plus bone powder; Group C, which will undergo apical surgery plus CGF (concentrated growth factors); and Group D, which will undergo apical surgery plus bone powder and CGF gel. Each group will consist of 18 patients, and all surgeries will be performed by the same experienced doctor. The participants will receive a 1-year follow-up with the assistance of a professional doctor, including questionnaire data and daily records of pain and swelling at 2, 6, and 12 hours and 7 days after the intervention. Cone-beam computed tomography (CBCT) images will also be taken before the surgery, immediately after the surgery, and at 2, 3, 4, 6, and 12 months post-surgery.

Eligibility Criteria:
Inclusion Criteria:

* 18 years old or above.
* Tooth with significant symptoms or with root apex bone tissue destruction that cannot be treated by non-surgical methods.
* The affected tooth is either an anterior tooth or a premolar.
* The size of the lesion during preoperative cone beam computed tomography (CBCT) coronal acquisition is at least 6 mm but not more than 12 mm.
* The affected tooth has undergone successful root canal treatment.
* CBCT shows intact lingual side bone plate in the apical region, with only buccal alveolar bone defect present.
* Good oral hygiene and compliance with medical instructions.

Exclusion Criteria:

* Severe periodontal destruction, with over 1/3 of the root length absorbed by alveolar bone.
* CBCT shows root fracture or root canal perforation.
* After root apex surgery, crown-root ratio ≤1:1.
* Presence of surgical contraindications, systemic and local factors that affect wound healing.
* Pregnant women and females planning to conceive within the next two years.